Standard Biotools (LAB) Free Cash Flow (2010 - 2026)

Standard Biotools (LAB) has 17 years of Free Cash Flow data on file, last reported at -$46.9 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$46.9 million, down 32.77% year-over-year; the trailing twelve-month figure through Mar 2026 was -$86.8 million (up 26.05% YoY), and the FY2025 annual result was -$75.2 million, up 48.24% from the prior year.
• Free Cash Flow declined to -$46.9 million in Q1 2026 per LAB's latest filing, from $5.8 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $5.8 million in Q4 2025 and troughed at -$63.3 million in Q1 2024.
• A 5-year average of -$23.8 million and a median of -$22.6 million in 2025 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow tumbled 3887.2% in 2022, then jumped 138.73% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$19.9 million in 2022, then soared by 43.28% to -$11.3 million in 2023, then sank by 32.1% to -$14.9 million in 2024, then jumped by 138.73% to $5.8 million in 2025, then slumped by 910.85% to -$46.9 million in 2026.
• Business Quant data shows LAB's Free Cash Flow at -$46.9 million in Q1 2026, $5.8 million in Q4 2025, and -$23.1 million in Q3 2025.